Journal ArticleDOI
Cardiac Resynchronization in Chronic Heart Failure
William T. Abraham,Westby G. Fisher,Andrew L. Smith,David B. Delurgio,Angel R. Leon,Evan Loh,Dusan Z. Kocovic,Milton Packer,Alfredo L. Clavell,David L. Hayes,Myrvin H. Ellestad,Robin J. Trupp,Jackie Underwood,Faith Pickering,Cindy Truex,Peggy McAtee,John C. Messenger +16 more
Reads0
Chats0
TLDR
Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.Abstract:
Background Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional clas...read more
Citations
More filters
Journal ArticleDOI
Usefulness of Tissue Doppler Velocity and Strain Dyssynchrony for Predicting Left Ventricular Reverse Remodeling Response After Cardiac Resynchronization Therapy
Cheuk-Man Yu,John Gorcsan,Gabe B. Bleeker,Qing Zhang,Martin J. Schalij,Matthew S. Suffoletto,Jeffrey W.H. Fung,David Schwartzman,Yat Sun Chan,Masaki Tanabe,Jeroen J. Bax +10 more
TL;DR: Parameters of tissue Doppler longitudinal velocity, but not longitudinal strain, predicted LV reverse remodeling after CRT, and the same conclusions were obtained in subgroup analyses of QRS duration and ischemic or nonischemic cause of heart failure.
Journal ArticleDOI
Longitudinal Strain Delay Index by Speckle Tracking Imaging A New Marker of Response to Cardiac Resynchronization Therapy
Pascal Lim,Adisai Buakhamsri,Zoran B. Popović,Neil L. Greenberg,Dimpi Patel,James D. Thomas,Richard A. Grimm +6 more
TL;DR: Use of the strain delay index with longitudinal strain by speckle tracking has a strong predictive value for predicting response to cardiac resynchronization therapy in both ischemic and nonischemic patients.
Journal ArticleDOI
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator
Guiqing Yao,Nick Freemantle,Melanie Calvert,Stirling Bryan,Jean-Claude Daubert,John G.F. Cleland +5 more
TL;DR: Long-term treatment with CRT-P appears cost-effective compared with medical therapy (MT) alone, and from a life-time perspective, assuming a reasonable life expectancy when receiving effective treatment for heart failure,CRT-ICD may also be considered cost- effective when compared with CRt-P + MT.
Journal Article
Ventricular Resynchronization: Pathophysiology and Identification of Responders
TL;DR: Biventricular and left ventricular resynchronization pacing therapies acutely improve systolic ventricular function and energetic efficiency in patients with heart failure and left-bundle-type intraventricular conduction delay.
Journal ArticleDOI
Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition.
Cheuk-Man Yu,Qing Zhang,Gabriel W.K. Yip,Pui-Wai Lee,Leo C.C. Kum,Yat-Yin Lam,Jeffrey W.H. Fung +6 more
TL;DR: Diastolic and/or systolic as synchrony was common in 61% of DHF patients despite narrow QRS complex, and the presence of asynchrony was not related to myocardial syStolic or diastolic function.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
Serge Cazeau,Christophe Leclercq,Thomas Lavergne,S Walker,Varma C,Cecilia Linde,Stéphane Garrigue,Lukas Kappenberger,G A Haywood,Massimo Santini,Bailleul C,Jean-Claude Daubert,Multisite Stimulation in Cardiomyopathies (Mustic) Study Investigators +12 more
TL;DR: In this article, transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle) were used to reduce ventricular asynchrony.
Journal Article
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure
Gordon H. Guyatt,Michael J. Sullivan,Penelope J. Thompson,Ernest L. Fallen,S. O. Pugsley,D W Taylor,Leslie B. Berman +6 more
TL;DR: It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
Journal ArticleDOI
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
Bertram Pitt,Philip A. Poole-Wilson,Robert Segal,Felipe Martinez,Kenneth Dickstein,A. John Camm,Marvin A. Konstam,Günter A.J. Riegger,George Klinger,James D. Neaton,Divakar Sharma,Balasamy Thiyagarajan +11 more
TL;DR: The ELITE II Losartan Heart Failure Survival Study as discussed by the authors showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an ACE inhibitor.